Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Cephalon Inc. v. Breckenridge Pharmaceutical Inc. et al.
1:14-cv-00671; filed May 27, 2014 in the District Court of Delaware

• Plaintiff:  Cephalon Inc.
• Defendants:  Breckenridge Pharmaceutical Inc.; Natco Pharma Ltd.

Infringement of U.S. Patent Nos. 8,445,524 ("Solid Forms of Bendamustine Hydrochloride," issued May 21, 2013), 8,436,190 ("Bendamustine Pharmaceutical Compositions," issued May 7, 2013), and 8,609,863 ("Bendamustine Pharmaceutical Compositions," issued December 17, 2013) following a Paragraph IV certification as part of Breckenridge's filing of an ANDA to manufacture a generic version of Cephalon's Treanda® (bendamustine hydrochloride, used to treat chronic lymphocytic leukemia and non-Hodgkin's lymphoma).  View the complaint here.

AstraZeneca AB v. Aurobindo Pharma Ltd. et al.
1:14-cv-00664; filed May 23, 2014 in the District Court of Delaware

• Plaintiff:  AstraZeneca AB
• Defendants:  Aurobindo Pharma Ltd.; Aurobindo Pharma USA Inc.

AstraZeneca AB v. Glenmark Generics Ltd. et al.
1:14-cv-00665; filed May 23, 2014 in the District Court of Delaware

• Plaintiff:  AstraZeneca AB
• Defendants:  Glenmark Generics Ltd.; Glenmark Generics Inc. USA

AstraZeneca AB v. Watson Laboratories Inc., et al.
1:14-cv-00666; filed May 23, 2014 in the District Court of Delaware

• Plaintiff:  AstraZeneca AB
• Defendants:  Watson Laboratories Inc.; Actavis Inc.; Actavis LLC

The complaints in these cases are substantially identical.  Infringement of U.S. Patent No. 7,951,400 ("Coated Tablet Formulation and Method," issued May 31, 2011) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of AstraZeneca's Onglyza® (saxagliptin hydrochloride, used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus).  View the Aurobindo complaint here.

AstraZeneca AB v. Wockhardt Bio AG et al.
1:14-cv-00667; filed May 23, 2014 in the District Court of Delaware

• Plaintiff:  AstraZeneca AB
• Defendants:  Wockhardt Bio AG; Wockhardt USA LLC

Infringement of U.S. Patent Nos. RE44,186 ("Cyclopropyl-Fused Pyrrolidine-Based Inhibitors of Dipeptidyl Peptidase IV and Method," issued April 30, 2013) and 7,951,400 ("Coated Tablet Formulation and Method," issued May 31, 2011) following a Paragraph IV certification as part of Wockhardt's filing of an ANDA to manufacture a generic version of AstraZeneca's Onglyza® (saxagliptin hydrochloride, used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus).  View the complaint here.

 

 

Topics:  AstraZeneca, Biotechnology, Cephalon, Patent Infringement, Patent Litigation, Patents, Pharmaceutical, Pharmaceutical Manufacturers, Pharmaceutical Patents

Published In: Civil Procedure Updates, Intellectual Property Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »